Clinical Trial Update: Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial completed evaluating LIPO-202 for reducing central abdominal bulging in obese adults, reporting safety and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Obesity
• Obesity

Drugs mentioned

• LIPO-202

Snippet

Sponsor: Neothetics, Inc | Conditions: Central Abdominal Bulging | Phase 2 | Status: COMPLETED